ArticleBioMed research international2026
In Vitro Screening of an FDA-Approved Chemical Library for Arylsulfatase A Using Fibroblast Cells Derived From Patients With MLD.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMetachromatic leukodystrophy (MLD) is a rare metabolic disease characterized by demyelination and inherited in an autosomal recessive manner. It is caused by mutations in the arylsulfatase A (ARSA) gene. When ARSA enzyme activity is lacking or reduced, sulfatides and lysosulfatides accumulate, particularly within the myelin sheath, resulting in various symptoms, including developmental delay and movement disorders. Gene therapy using hematopoietic stem cells has been developed and approved for MLD; however, the long-term risks associated with lentiviral vectors remain uncertain. Therefore, expanding the available therapeutic options for patients with MLD remains essential.
methodsThis study is aimed at exploring two potential drugs that may induce heat-shock protein, along with 765 FDA-approved drugs that might enhance ARSA enzyme activity, using four fibroblast cell lines derived from patients with MLD.
resultsFibroblasts derived from patients with MLD exhibited low ARSA enzyme activities and increased sulfatide accumulation. Geranylgeranylacetone, an HSP70 inducer, increased the enzyme activity, while arimoclomol, an HSP coinducer, did not affect it. Furthermore, a screening test revealed that two of the 765 FDA-approved drugs increased the enzyme activity in MLD fibroblasts.
conclusionThese results lay the groundwork for future research into the development of new therapeutic options for MLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.